Sanofi Granted Sciwind Biosciences Rights to Sanofi's GIP Receptor Agonist Program

HANGZHOU, China and SAN FRANCISCO/PRNewswire/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced that it has signed a global, exclusive license agreement with Sanofi to develop and commercialize Sanofi’s long-lasting glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, with the lead candidate currently under preclinical development.

In the terms of the agreement, Sanofi granted exclusive worldwide rights to Sciwind to develop, manufacture and commercialize Sanofi’s GIP receptor agonists for all applicable indications. GIP receptor agonists have shown potential to enhance treatment efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists in treating obesity and diabetes as well as to improve their overall safety and tolerability profile. Sciwind plans to develop the lead GIP receptor agonist as part of combination with its GLP-1 peptide candidate, XW003 which is currently being evaluated in Phase 2 studies, for the treatment of diabetes, obesity and NASH.

“We are excited to enter this agreement with Sanofi as we advance our goal of building a portfolio of best-in-class treatments for patients living with metabolic disease around the world,” said Dr. Hai Pan, founder and CEO of Sciwind. “We look forward to the opportunity to combine Sanofi’s long-lasting GIP receptor agonist with Sciwind’s GLP-1 drug candidates which we hope will lead to development of more efficacious and better tolerated combination therapies for metabolic conditions.”